ERS Genomics Ltd
ERS Genomics is a global leader in CRISPR/Cas9 gene editing technology licensing, providing broad access to foundational CRISPR/Cas9 intellectual property. Founded on the Nobel Prize-winning discoveries of Emmanuelle Charpentier and Jennifer Doudna, ERS licenses over 85 patents worldwide, supporting innovation across industries such as biotech, pharma, agriculture, and synthetic biology. The company aims to democratize access to CRISPR technology, enabling researchers and companies to develop life-changing treatments and technologies responsibly and efficiently.
Industries
Nr. of Employees
small (1-50)
ERS Genomics Ltd
Products
Start‑up Guide (downloadable)
A downloadable guide aimed at startups describing licensing options and practical steps for accessing CRISPR/Cas9 intellectual property.
Advancing the Frontiers of Biotherapeutics (downloadable)
A technical/downloadable brief on applications of CRISPR/Cas9 in therapeutic protein production and biotherapeutics.
The facts about CRISPR/Cas9 Licensing (downloadable)
A short downloadable briefing that addresses common questions and misperceptions about licensing CRISPR/Cas9.
Start‑up Guide (downloadable)
A downloadable guide aimed at startups describing licensing options and practical steps for accessing CRISPR/Cas9 intellectual property.
Advancing the Frontiers of Biotherapeutics (downloadable)
A technical/downloadable brief on applications of CRISPR/Cas9 in therapeutic protein production and biotherapeutics.
The facts about CRISPR/Cas9 Licensing (downloadable)
A short downloadable briefing that addresses common questions and misperceptions about licensing CRISPR/Cas9.
Services
CRISPR/Cas9 licensing for research and commercial use
Negotiate and grant licences that provide freedom-to-operate under a foundational CRISPR/Cas9 patent portfolio for internal research and many commercial applications outside direct human gene and cell therapy.
Express licensing platform for early-stage organisations
A streamlined licensing pathway designed for small organisations and startups to obtain a non-exclusive internal-research licence with simplified eligibility criteria and faster onboarding.
IP advisory and patent landscape support
Advisory support on the patent landscape, ongoing monitoring of legal developments, and structuring licence terms to address freedom-to-operate risks.
Partnership facilitation for R&D and commercial collaborations
Negotiate and execute licence agreements and collaboration terms with service providers, CROs and industry partners to enable CRISPR-enabled programs and preclinical tool development.
CRISPR/Cas9 licensing for research and commercial use
Negotiate and grant licences that provide freedom-to-operate under a foundational CRISPR/Cas9 patent portfolio for internal research and many commercial applications outside direct human gene and cell therapy.
Express licensing platform for early-stage organisations
A streamlined licensing pathway designed for small organisations and startups to obtain a non-exclusive internal-research licence with simplified eligibility criteria and faster onboarding.
IP advisory and patent landscape support
Advisory support on the patent landscape, ongoing monitoring of legal developments, and structuring licence terms to address freedom-to-operate risks.
Partnership facilitation for R&D and commercial collaborations
Negotiate and execute licence agreements and collaboration terms with service providers, CROs and industry partners to enable CRISPR-enabled programs and preclinical tool development.
Expertise Areas
- Intellectual property licensing and management (gene editing IP)
- CRISPR/Cas9 platform applications
- Preclinical model development (engineered cell lines, organoids, PDX)
- Synthetic biology and industrial bioproduction
Key Technologies
- CRISPR/Cas9 gene editing
- Base editing
- Prime editing
- CRISPRa/CRISPRi (CRISPR-based gene regulation)